Evolution of low HER2 expression between early and advanced-stage breast cancer.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.12.022
Abstract: BACKGROUND Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the… read more here.
Keywords: her2 expression; expression; breast cancer; her2 low ... See more keywords
Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in cancer biology"
DOI: 10.1016/j.semcancer.2020.02.016
Abstract: The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on… read more here.
Keywords: her2 low; breast; breast cancer; evaluation ... See more keywords
HER2-low breast cancers: Current insights and future directions.
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in diagnostic pathology"
DOI: 10.1053/j.semdp.2022.07.003
Abstract: In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new "HER2-low" category in breast… read more here.
Keywords: low breast; breast; pathology; her2 low ... See more keywords
HER2-Low Breast Cancers.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqab117
Abstract: OBJECTIVES Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ and negative in… read more here.
Keywords: low breast; her2 low; breast; breast cancer ... See more keywords
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac184
Abstract: OBJECTIVES We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort. METHODS A total of 114 breast cancer specimens were stained by HercepTest (Agilent Dako) and PATHWAY… read more here.
Keywords: agreement; interobserver interantibody; breast; her2 low ... See more keywords
HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Cancer Prevention"
DOI: 10.1097/cej.0000000000000781
Abstract: Human epidermal growth factor 2 (HER2)–low breast cancers, defined as tumors exhibiting a HER2 IHC score of 1+ or 2+ nonamplified, represent an emerging targetable entity in the clinicopathologic landscape of breast cancer. Traditionally considered… read more here.
Keywords: oncology; breast; her2 low; treatment ... See more keywords
Refining the definition of HER2‐low class in invasive breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Histopathology"
DOI: 10.1111/his.14780
Abstract: Emerging evidence indicates that breast cancer (BC) patients whose tumours express HER2 protein without HER2 gene amplification (HER2‐low), can benefit from antibody–drug conjugates (ADC). However, the current definition of HER2‐low BC remains incomplete with low… read more here.
Keywords: breast cancer; her2 low; her2; definition her2 ... See more keywords
Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/4364151
Abstract: Aim It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival… read more here.
Keywords: index; her2; status; her2 low ... See more keywords
Abstract 961: HER2-low expression in patients with advanced or metastatic solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-961
Abstract: Introduction: HER2 protein expression by immunohistochemistry (IHC) has been the main testing method for breast and gastric cancers. Much remains unknown about the frequency of HER2-low (IHC 1+ or 2+) expression and the change of… read more here.
Keywords: her2; expression; ihc; her2 low ... See more keywords
Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs22-p2-23-14
Abstract: Background: The DESTINY-Breast04 clinical trial demonstrated the superiority of trastuzumab deruxtecan (T-DXd) versus physician’s choice chemotherapy in HER2-low [immunohistochemistry (IHC) staining score 1+ or 2+ with no gene amplification by in-situ hybridization] metastatic breast cancer.… read more here.
Keywords: breast; her2; expression; ihc ... See more keywords
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02318
Abstract: PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated… read more here.
Keywords: her2 low; breast cancer; patients her2; antitumor activity ... See more keywords